Journal pdf

Definition and Treatment Phases

• Venous Thromboembolism (VTE) encompasses both Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
• Deep Vein Thrombosis (DVT): Defined as a blood clot located in a deep vein, most commonly occurring in the leg.
• Pulmonary Embolism (PE): Defined as a clot that travels to and blocks the pulmonary arteries within the lungs.
• CHEST Treatment Phases:
  • Initiation Phase: Encompasses the first $0-21$ days of treatment.
  • Treatment Phase: Encompasses the first $3$ months of treatment.
  • Extended Phase: Follows the initial $3$ months when ongoing prevention of VTE recurrence is indicated.

Clinical Signs and Symptoms

• Deep Vein Thrombosis (DVT) - Associated with leg presentation:
  • Unilateral swelling or edema
  • Pain and tenderness
  • Warmth, erythema, or skin discoloration
• Pulmonary Embolism (PE) - Associated with lung presentation:
  • Sudden onset shortness of breath (dyspnea)
  • Pleuritic chest pain
  • Tachypnea, tachycardia, and hypoxemia
  • Cough or hemoptysis
  • Severe or life-threatening presentation: Syncope, hypotension, and shock

Diagnostic Approach and Workup

• Step 1: Assess clinical pre-test probability.
• Step 2: D-dimer Testing:
  • Utilized to rule out VTE in appropriate low-risk or intermediate-risk patients.
  • A positive D-dimer test alone is non-specific and does not diagnose VTE.
• Step 3: Evaluation for Suspected DVT:
  • Compression venous ultrasound is the diagnostic imaging study of choice.
• Step 4: Evaluation for Suspected PE:
  • Computed Tomography (CT) pulmonary angiography is the primary diagnostic imaging modality.
  • Ventilation/Perfusion (V/Q) scan is utilized when CT pulmonary angiography is inappropriate or unavailable.
• Management While Awaiting Diagnostic Testing:
  • CHEST guidelines support empiric parenteral anticoagulation when clinical suspicion of VTE is high.
  • Empiric parenteral anticoagulation is supported for intermediate suspicion if diagnostic testing is expected to be delayed by more than $4$ hours ($> 4$ hours).

Treatment Overview and Core Anticoagulation Rules

• Primary Therapeutic Goal: Prevent clot extension, recurrent VTE, and death while minimizing bleeding risk.
• Standard Acute Duration: Anticoagulate most acute DVT or PE cases for a minimum duration of $3$ months if no contraindications exist.
• Guideline Preference: CHEST guidelines express a preference for direct-acting oral anticoagulants (apixaban, dabigatran, edoxaban, or rivaroxaban) over warfarin or other Vitamin K Antagonists (VKAs) during the treatment phase.
• Mandatory Bridging and Lead-in Rules:
  • Apixaban and Rivaroxaban: Do NOT require a parenteral heparin lead-in.
  • Dabigatran and Edoxaban: Require $5-10$ days of initial parenteral anticoagulation lead-in therapy prior to initiation.
  • Warfarin: Requires overlapping parenteral anticoagulation therapy for a minimum of $5$ days ($\ge 5$ days) AND until the International Normalized Ratio (INR) is $\ge 2.0$ for at least $24$ hours ($\ge 24$ hours).

Management of Deep Vein Thrombosis (DVT)

• Proximal DVT:
  • Indicated for full therapeutic anticoagulation.
• Isolated Distal DVT:
  • Mild symptoms or no risk factors for extension: Manage with serial compression ultrasounds for $2$ weeks (typically performed at days $0$, $7$, and $14$).
  • Serial imaging shows no extension: Anticoagulation is not required.
  • Serial imaging shows extension (distally or proximally): Initiate full therapeutic anticoagulation.
  • Severe symptoms or high risk of extension at presentation: Initiate therapeutic anticoagulation immediately.
  • Treatment Strategy: When treated, isolated distal DVT utilizes the exact same anticoagulation approach and regimen as proximal DVT.

Management of Pulmonary Embolism (PE)

• Hemodynamically Stable PE:
  • Therapeutic anticoagulation serves as primary medical management.
  • Selected low-risk patients may be treated in the outpatient setting if follow-up, home situation, and medical access are adequate.
• PE with Hypotension (e.g., Systolic Blood Pressure $SBP < 90$ mmHg):
  • Consider systemic thrombolytic therapy if patient bleeding risk is acceptable.
• PE without Hypotension:
  • Do not routinely administer systemic thrombolysis.
• Clinical Deterioration Despite Anticoagulation:
  • Rescue thrombolytic therapy may be considered.
• Subsegmental PE:
  • Clinical surveillance without anticoagulation is appropriate only in carefully selected patients with low recurrence risk and no evidence of proximal DVT.

Anticoagulant Pharmacotherapy Profiles

• Apixaban:
  • Acute VTE Dose and Frequency: $10$ mg PO BID for $7$ days, then $5$ mg PO BID.
  • Key Administration Rule and Duration: No parenteral heparin lead-in required. Treatment duration $\ge 3$ months. Extended therapy reduced dose is $2.5$ mg PO BID.
  • Safety and Monitoring: Risk of bleeding and anemia. Monitor complete blood count (CBC), renal function, and hepatic function.
• Rivaroxaban:
  • Acute VTE Dose and Frequency: $15$ mg PO BID with food for $21$ days, then $20$ mg PO daily with food.
  • Key Administration Rule and Duration: No parenteral heparin lead-in required. Treatment duration $\ge 3$ months. Extended therapy reduced dose is $10$ mg PO daily.
  • Safety and Monitoring: Risk of bleeding, anemia, and gastrointestinal (GI) bleeding. Monitor CBC, renal function, and hepatic function.
• Dabigatran:
  • Acute VTE Dose and Frequency: Following $5-10$ days of parenteral lead-in, administer $150$ mg PO BID.
  • Key Administration Rule and Duration: Requires initial parenteral lead-in. Treatment duration $\ge 3$ months when indicated.
  • Safety and Monitoring: Risk of bleeding and dyspepsia. Monitor CBC and renal function.
• Edoxaban:
  • Acute VTE Dose and Frequency: Following $5-10$ days of parenteral lead-in, administer $60$ mg PO daily (Note: Specific dose reduction criteria are not fully detailed in the CHEST treatment guideline compendium).
  • Key Administration Rule and Duration: Requires initial parenteral lead-in. Treatment duration $\ge 3$ months when indicated.
  • Safety and Monitoring: Risk of bleeding. Dose considerations required based on renal function, body weight, and drug interactions.
• Enoxaparin:
  • Acute VTE Dose and Frequency: Commonly $1$ mg/kg SC q12h.
  • Key Administration Rule and Duration: Utilized as acute parenteral treatment or as a bridge to warfarin therapy. Dose adjustments may be required for renal impairment.
  • Safety and Monitoring: Risk of bleeding, Heparin-Induced Thrombocytopenia (HIT), and injection-site hematomas. Monitor CBC, platelet count, and renal function.
• Unfractionated Heparin (UFH):
  • Acute VTE Dose and Frequency: Intravenous (IV) bolus followed by continuous IV infusion titrated per institutional activated partial thromboplastin time (aPTT) or anti-Factor Xa protocol.
  • Key Administration Rule and Duration: Short-acting inpatient therapy option, allowing rapid titration or reversal.
  • Safety and Monitoring: Risk of bleeding and HIT. Monitor CBC, platelet count, and aPTT or anti-Factor Xa levels.
• Fondaparinux:
  • Acute VTE Dose and Frequency: Weight-based subcutaneous (SC) daily dosing. For high-risk superficial venous thrombosis (SVT), dose is $2.5$ mg SC daily.
  • Key Administration Rule and Duration: SVT treatment regimen duration is $45$ days.
  • Safety and Monitoring: Risk of bleeding. High risk of drug accumulation in renal impairment.
• Warfarin:
  • Acute VTE Dose and Frequency: Dose individualized to achieve a target INR range of $2.0-3.0$
  • Key Administration Rule and Duration: Requires parenteral overlap for $\ge 5$ days AND until INR is $\ge 2.0$ for $\ge 24$ hours.
  • Safety and Monitoring: Risk of bleeding, skin necrosis, purple toe syndrome, teratogenicity, and extensive drug and food interactions.

Duration of Anticoagulation Therapy

• Reassessment at $3$ Months: Evaluate the underlying etiology and provoking factors of the VTE event.
• Major Transient Risk Factor (e.g., surgery, major trauma):
  • Stop anticoagulation after the initial $3$ months of treatment. CHEST guidelines recommend against extended therapy.
• Minor Transient Risk Factor:
  • Generally do not pursue extended therapy beyond $3$ months.
• Unprovoked VTE or Persistent Risk Factor:
  • Consider extended DOAC therapy if the reduction in VTE recurrence risk outweighs individual bleeding risk.
• Active Cancer:
  • Extended anticoagulation therapy without a scheduled stop date is preferred.
• Dosing Strategy for Extended Therapy:
  • CHEST guidelines suggest apixaban $2.5$ mg BID or rivaroxaban $10$ mg daily over full standard treatment doses when extended prevention is selected.

Side Effects and Adverse Reactions

• Primary Universal Adverse Effect: Bleeding.
• Direct-Acting Oral Anticoagulants (DOACs):
  • Bleeding and anemia.
  • Dabigatran specifically causes dyspepsia and upper gastrointestinal distress.
• Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH):
  • Bleeding and Heparin-Induced Thrombocytopenia (HIT).
  • Prolonged heparin exposure increases the risk of osteoporosis.
• Warfarin:
  • Bleeding, skin necrosis, purple toe syndrome, teratogenicity, and multiple drug/food interactions.
• Thrombolytics:
  • Major bleeding and intracranial hemorrhage.

Clinical Monitoring Framework

• Parameter 1: Efficacy Monitoring (Is treatment working?):
  • Reduction in DVT pain and swelling.
  • Improvement in PE dyspnea and systemic oxygenation.
  • Prevention of recurrent VTE events.
• Parameter 2: Safety Monitoring (Is the patient bleeding?):
  • Physical signs: Bruising, hematuria, melena, or hematemesis.
  • Laboratory signs: Falling hemoglobin (Hgb) or hematocrit (Hct) levels.
  • Hemodynamic signs: Unexplained hypotension.
• Parameter 3: Appropriate Drug Selection (Is the regimen still safe and appropriate?):
  • Regular assessment of CBC, platelet count, Serum Creatinine (SCr) / Creatinine Clearance (CrCl), and hepatic function.
  • Review patient adherence and screen for potential drug interactions.
• Drug-Specific Monitoring Rules:
  • UFH: Monitor aPTT or anti-Factor Xa levels and platelet counts.
  • Warfarin: Monitor INR (target range $2.0-3.0$).
  • DOACs: Do not require routine INR or aPTT monitoring.

Seven-Step Assessment and Plan Order

1. Confirm diagnosis of DVT versus PE and evaluate disease severity and hemodynamic status.
2. Screen for bleeding contraindications and obtain baseline CBC, platelet count, and renal function panel.
3. Select specific anticoagulant based on renal function, drug interactions, bleeding risk, active cancer or pregnancy status, oral route tolerance, and medication access.
4. Administer correct acute initiation dose and implement parenteral lead-in/bridging where indicated.
5. Maintain treatment for a minimum of $3$ months when indicated.
6. Educate patient regarding strict adherence, bleeding warning signs, and VTE recurrence signs.
7. Formal Reassessment at $3$ Months: Make decision to STOP or EXTEND therapy.

Contingency Plans and Special Complications

• Management of Bleeding Complications:
  • Hold anticoagulant therapy when clinically appropriate.
  • Provide hemodynamic stabilization and locate the source of bleeding.
  • Check relevant baseline laboratory tests.
  • Administer agent-specific reversal agents or supportive care measures as indicated.
• Management of New or Recurrent VTE on Therapy:
  • Confirm true VTE recurrence with objective testing.
  • Verify patient medication adherence.
  • Confirm correct weight/renal dosing schedule.
  • Evaluate renal function, drug interactions, malabsorption, or newly emergent provoking factors.
  • Revise therapeutic regimen with specialist input.
• Management of Hemodynamically Unstable PE:
  • Execute urgent clinical escalation.
  • Reevaluate indications for systemic thrombolysis, catheter-directed intervention, or surgical embolectomy.
• Anticoagulation Contraindications:
  • For acute proximal DVT or acute PE where anticoagulation is strictly contraindicated, CHEST recommends placement of an Inferior Vena Cava (IVC) filter.
  • The IVC filter should be retrieved as soon as the patient can safely tolerate anticoagulation.

Follow-Up and Discharge Planning

• Pre-Discharge Verification:
  • Confirm exact drug name, dose, administration frequency, and planned duration.
  • Re-verify renal appropriateness and evaluate potential drug-drug interactions.
  • Confirm financial/insurance access and establish a clear adherence plan.
  • Provide complete education on bleeding precautions and missed-dose protocols.
• Urgent Medical Care Warning Flags:
  • Worsening shortness of breath or acute chest pain
  • Syncope
  • Hemoptysis
  • Rapidly increasing unilateral leg swelling
  • Uncontrolled bleeding
  • Black or bloody stools, or vomiting blood
  • Severe sudden headache or focal neurological changes
• Follow-up Protocol:
  • Early post-discharge clinical review.
  • Periodic outpatient lab monitoring as appropriate.
  • Formal, dedicated reassessment at $3$ months.

Management of Special Clinical Situations

• High-Risk Superficial Venous Thrombosis (SVT):
  • Treat with anticoagulation for $45$ days.
  • CHEST guidelines suggest fondaparinux $2.5$ mg SC daily.
  • If daily parenteral injections are non-feasible, rivaroxaban $10$ mg PO daily is a reasonable alternative.
• Upper-Extremity DVT (UEDVT - Axillary or more proximal):
  • Manage with anticoagulation alone for a minimum of $3$ months.
  • If a central venous catheter is functional and required, it may remain in place; anticoagulation should be continued while the catheter remains present.
• Cerebral Venous Thrombosis:
  • Manage with anticoagulation for a minimum of $3$ months.
• Confirmed Antiphospholipid Syndrome (APS):
  • Treat with Vitamin K Antagonists (VKA) targeted to an INR of $2.5$ (range $2.0-3.0$) in preference to DOACs during the treatment phase.

Guideline Background and Core Principles

• Guideline Context: CHEST Antithrombotic Therapy for VTE Disease compendium of recommendations derived from the $2012$ AT9 guidelines, updated in $2016$, and further updated in $2021$.
• Four Essential CHEST Points to Remember:
  1. Acute VTE requires a minimum of $3$ months of therapeutic anticoagulation.
  2. DOACs are generally preferred over VKAs for treatment-phase DVT/PE management.
  3. IVC filters should not be routinely added to therapy if anticoagulation can be safely administered.
  4. The decision to extend therapy beyond $3$ months depends on whether the event was provoked, individual recurrence risk, and individual bleeding risk.

List of Standard Abbreviations

• VTE: Venous Thromboembolism
• DVT: Deep Vein Thrombosis
• PE: Pulmonary Embolism
• DOAC: Direct-Acting Oral Anticoagulant
• VKA: Vitamin K Antagonist
• LMWH: Low-Molecular-Weight Heparin
• UFH: Unfractionated Heparin
• INR: International Normalized Ratio
• IVC: Inferior Vena Cava
• SVT: Superficial Venous Thrombosis
• UEDVT: Upper-Extremity Deep Vein Thrombosis
• HIT: Heparin-Induced Thrombocytopenia
• SBP: Systolic Blood Pressure
• SC: Subcutaneous
• PO: Per Os (by mouth)
• BID: Twice Daily
• aPTT: Activated Partial Thromboplastin Time